RxDoctor Payments Data

Minni Malhotra, MD

Family Medicine · Houston, TXNPI 1528257508

Payments from drug & device makers

$31,205in general payments, 2019–2025

Across 124 payments — averaging $251.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$30K
  • Lilly USA, LLC$263
  • Eisai Inc.$216
  • AbbVie$179
  • Novo Nordisk$129
  • Johnson & Johnson$129
  • plus $528 from 14 others

What the payments were for

  • Speaking & faculty fees$26,20084%
  • Travel & lodging$2,2877%
  • Food & beverage$2,7179%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,205 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$44,222
Medicare patients
183
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$59,319
OzempicSemaglutide59$58,603
JardianceEmpagliflozin82$27,905
TrulicityDulaglutide27$26,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,044
RexultiBrexpiprazole12$17,756
JanuviaSitagliptin Phosphate62$16,915
MyrbetriqMirabegron32$14,407
EntrestoSacubitril/Valsartan29$12,005
XareltoRivaroxaban35$10,295
Xtampza ErOxycodone Myristate12$8,760
LinzessLinaclotide15$8,752
Repatha SureclickEvolocumab15$8,295
Tresiba Flextouch U-100Insulin Degludec26$7,703
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen307$7,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$129$58,60359 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$32$38,748112 claims
Lilly USA, LLCTrulicity$263$26,93227 claims
GSKTrelegy Ellipta$43$18,04428 claims
Otsuka America Pharmaceutical, Inc.Rexulti$42$17,75612 claims
NovartisEntresto$67$12,00529 claims
Johnson & JohnsonXarelto$129$10,29535 claims
AbbVieLinzess$179$8,75215 claims
AstraZenecaSymbicort$46$5,84323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →